Caris Life Sciences, Inc. Common Stock (CAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has a cash flow conversion efficiency ratio of 0.055x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($32.88 Million) by net assets ($593.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Caris Life Sciences, Inc. Common Stock to measure how much of total assets are equity-financed.
Caris Life Sciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Caris Life Sciences, Inc. Common Stock cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Caris Life Sciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Century Aluminum Company
NASDAQ:CENX
|
0.053x |
|
X-Energy, Inc. Class A Common Stock
NASDAQ:XE
|
-0.064x |
|
BIDVEST SP.ADR/2 RC-05
F:NQL
|
N/A |
|
Aura Minerals Inc. Common Shares
NASDAQ:AUGO
|
0.368x |
|
Linamar Corporation
TO:LNR
|
0.040x |
|
HLA GROUP CORP LTD
SHG:600398
|
0.126x |
|
Asseco Poland S.A.
WAR:ACP
|
0.114x |
|
Shanghai Friendess Electronics Tech
SHG:688188
|
0.037x |
Annual Cash Flow Conversion Efficiency for Caris Life Sciences, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Caris Life Sciences, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $577.31 Million | $83.16 Million | 0.144x | +46.79% |
| 2024-12-31 | $-2.50 Billion | $-245.20 Million | 0.098x | -23.77% |
| 2023-12-31 | $-2.14 Billion | $-276.10 Million | 0.129x | -23.31% |
| 2022-12-31 | $-1.70 Billion | $-285.71 Million | 0.168x | -57.45% |
| 2020-12-31 | $702.24 Million | $277.02 Million | 0.394x | +7.66% |
| 2019-12-31 | $693.24 Million | $254.00 Million | 0.366x | +42.90% |
| 2018-12-31 | $701.13 Million | $179.77 Million | 0.256x | -6.84% |
| 2017-12-31 | $563.85 Million | $155.19 Million | 0.275x | -2.58% |
| 2016-12-31 | $457.50 Million | $129.26 Million | 0.283x | -11.57% |
| 2015-12-31 | $461.26 Million | $147.37 Million | 0.319x | +1.30% |
| 2014-12-31 | $442.90 Million | $139.69 Million | 0.315x | +5.43% |
| 2013-12-31 | $415.13 Million | $124.19 Million | 0.299x | -2.87% |
| 2012-12-31 | $346.85 Million | $106.83 Million | 0.308x | +6.25% |
| 2011-12-31 | $248.74 Million | $72.11 Million | 0.290x | +35.07% |
| 2010-12-31 | $197.67 Million | $42.42 Million | 0.215x | -10.04% |
| 2009-12-31 | $129.10 Million | $30.80 Million | 0.239x | -1.06% |
| 2008-12-31 | $113.79 Million | $27.44 Million | 0.241x | +11988.54% |
| 2007-12-31 | $131.15 Million | $-266.00K | -0.002x | -100.67% |
| 2006-12-31 | $27.75 Million | $8.38 Million | 0.302x | -66.15% |
| 2005-12-31 | $32.99 Million | $29.41 Million | 0.891x | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more